Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Revenue - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Mereo BioPharma (MREO) Cost of Revenue (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Cost of Revenue for 2 consecutive years, with $100000.0 as the latest value for Q2 2025.

  • Quarterly Cost of Revenue changed N/A to $100000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $100000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $133000.0 for FY2025, N/A changed from the prior year.
  • Cost of Revenue for Q2 2025 was $100000.0 at Mereo BioPharma, up from -$273000.0 in the prior quarter.
  • The five-year high for Cost of Revenue was $3.4 million in Q2 2023, with the low at -$273000.0 in Q4 2023.